Telix Pharmaceuticals to Highlight Urology Advancements at ASCO 2025
Telix Pharmaceuticals to Showcase Urology Pipeline at ASCO GU 2025
Telix Pharmaceuticals Limited (NASDAQ: TLX, ASX: TLX) is preparing to unveil its latest advancements in urological therapies at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2025). This prestigious event will take place in San Francisco from February 13 to 15, showcasing Telix's commitment to innovation in cancer treatment.
Presentations Highlighting Innovative Cancer Therapies
Dr. David N. Cade, Telix's Group Chief Medical Officer, has expressed enthusiasm about the company's significant presence at the symposium with four pivotal presentations. These sessions will illustrate the distinctiveness and depth of Telix’s therapeutic portfolio within the urology sector, alongside their advances in precision medicine. Notably, preliminary data from the CUPID study will be shared, marking the first presentation of this study at a medical congress and highlighting Telix's promising alpha therapy candidate for prostate cancer.
Key Trials and Impact
One prominent trial to be featured is the ProstACT GLOBAL study, the first Phase 3 trial evaluating TLX591, Telix’s lead rADC therapy candidate. This trial focuses on patients with PSMA-positive mCRPC who have not responded to earlier androgen receptor pathway inhibitors. The trial is currently actively recruiting patients across the United States and Asia Pacific, with a focus on its potential impact on treatment outcomes.
Innovations in Kidney Cancer Treatment
In addition to prostate cancer advancements, Telix is also making strides in kidney cancer treatment. Researchers for the STARLITE-1 and STARLITE-2 investigator-initiated trials will provide updates during ASCO GU. These critical studies are exploring the efficacy of TLX250, Telix’s rADC candidate targeting carbonic anhydrase IX (CAIX) in combination with immunotherapy for treatment-naïve and late-stage kidney cancer patients.
ASCO GU 2025 Presentation Schedule
Here are the details of the planned presentations for Telix during the ASCO GU 2025:
Title: A Phase 3 Study of 177Lu-rosoptamab Tetraxetan Plus Standard of Care vs. Standard of Care Alone in Patients with Metastatic Castration-Resistant Prostate Cancer
Date and Time: February 13, 2025 | 11:25 AM – 12:45 PM (PST)
Presenter: Oliver Sartor, MD, Mayo Clinic
Type: Trials in Progress Poster Session
Location: Level 1, West Hall | On Demand
Abstract: TPS303
Poster Bd: M22
Title: CUPID (Cu-TLX592 Phase 1 PK, Biodistribution & Dosimetry): A Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
Date and Time: February 13, 2025 | 11:25 AM – 12:45 PM (PST)
Presenter: David N. Cade, MD, Telix Pharmaceuticals
Type: Poster Session
Location: Level 1, West Hall | On Demand
Abstract: 177
Poster Bd: E16
Title: STARLITE-2: Phase 2 Study of Nivolumab plus Lutetium-labeled Anti–Carbonic Anhydrase IX (CAIX) Monoclonal Antibody Girentuximab in Patients with Advanced ccRCC
Date and Time: February 15, 2025 | 7:10 AM – 8:10 AM (PST)
Presenter: Darren Feldman, MD, Memorial Sloan Kettering Cancer Center
Type: Trials in Progress Poster Session
Location: Level 1, West Hall | On Demand
Abstract: TPS608
Poster Bd: K9
Title: STARLITE-1: Phase 1b/2 Study of Combination Lu Girentuximab (TLX250) Plus Cabozantinib and Nivolumab in Treatment Naïve Patients with Advanced ccRCC
Date and Time: February 15, 2025 | 7:10 AM – 8:10 AM (PST)
Presenter: Eric Jonasch, MD, The University of Texas, MD Anderson Cancer Center
Type: Trials in Progress Poster Session
Location: Level 1, West Hall | On Demand
Abstract: TPS614
Poster Bd: K15
About Telix Pharmaceuticals
Telix is a biopharmaceutical company dedicated to the innovation and commercial deployment of therapeutic and diagnostic radiopharmaceuticals. Based out of Melbourne, Australia, Telix operates on a global scale, with a presence in key regions such as the United States, Canada, Europe, and Japan. Its mission revolves around addressing critical unmet needs in oncology and rare diseases through a robust product pipeline.
Innovative Products and Regulatory Achievements
Among its key innovations is the lead prostate imaging product, gallium-68 gozetotide injection (Illuccix), which has received approval from the FDA and other regulatory bodies globally. Furthermore, Telix has introduced technetium-99m besilesomab, an imaging agent for osteomyelitis, approved across multiple European countries and Mexico.
Contact Information for Investor Relations
For inquiries relating to investor relations, please reach out to:
Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com
Frequently Asked Questions
What is Telix Pharmaceuticals focusing on at ASCO GU 2025?
Telix will showcase its advancements in therapeutic programs related to prostate and kidney cancer during the symposium.
Who is presenting Telix's research findings at the conference?
Notable presenters include Dr. Oliver Sartor and Dr. David N. Cade, among others, who will share vital information regarding the company's clinical trials.
What is the significance of the CUPID study?
The CUPID study aims to demonstrate the efficacy of TLX592, a targeted alpha therapy candidate in development for prostate cancer.
Where can interested parties find more information about Telix Pharmaceuticals?
Updates are available through Telix's official website and their social media channels.
What is the primary goal of Telix Pharmaceuticals?
Telix focuses on developing innovative therapeutic solutions to address significant unmet medical needs in oncology and rare diseases.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
